Koers Auris Medical Holding AG Nasdaq
Aandelen
CH0249375764
Biotechnologie & Medisch Onderzoek
Omzet 2024 * | - | Omzet 2025 * | - | Marktkapitalisatie | 3,46 mln. 3,79 mln. 3,54 mln. |
---|---|---|---|---|---|
Nettowinst (verlies) 2024 * | - | Nettowinst (verlies) 2025 * | - | EV/omzet 2024 * | - |
Nettoliquiditeiten 2024 * | - 0 0 | Nettoliquiditeiten 2025 * | - 0 0 | EV/omzet 2025 * | - |
K/w-verhouding 2024 * |
-
| K/w-verhouding 2025 * |
-
| Werknemers | - |
Dividendrendement 2024 * |
-
| Dividendrendement 2025 * |
-
| Vrij verhandelbaar | 99,11% |
Recentste transcriptie over Auris Medical Holding AG
Managers | Titel | Leeftijd | Van |
---|---|---|---|
Thomas Meyer
CEO | Chief Executive Officer | 56 | 01-04-03 |
Marcel Gremaud
DFI | Director of Finance/CFO | 66 | 01-11-21 |
Covadonga Pañeda
COO | Chief Operating Officer | 51 | - |
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
Alain Munoz
BRD | Director/Board Member | 75 | 01-03-18 |
Mats Blom
BRD | Director/Board Member | 59 | 01-04-17 |
Thomas Meyer
CEO | Chief Executive Officer | 56 | 01-04-03 |
Vaira. 1 jan. | Kapi. | |
---|---|---|
-2,31% | 103 mld. | |
+0,56% | 95,28 mld. | |
+1,69% | 22,15 mld. | |
-17,37% | 21,02 mld. | |
-9,30% | 18,15 mld. | |
-41,01% | 16,74 mld. | |
-14,85% | 16,05 mld. | |
+3,21% | 13,68 mld. | |
+33,54% | 12,17 mld. |